|
Market Closed -
Australian S.E.
13:10:20 08/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 181.46 AUD | -0.29% |
|
-1.50% | +5.10% |
| 09:06pm | Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 | DJ |
| 10-07 | CSL's Alentis Licensing Deal Low-Risk, Low-Reward, RBC Capital Markets Says | MT |
Company Valuation: CSL Limited
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 89,299 | 89,052 | 95,184 | 76,024 | 38,015 | 60,438 | - | - |
| Change | - | -0.28% | 6.89% | -20.13% | -50% | 58.98% | - | - |
| Enterprise Value (EV) 1 | 88,520 | 99,731 | 105,710 | 85,005 | 47,398 | 69,670 | 69,357 | 68,841 |
| Change | - | 12.66% | 5.99% | -19.59% | -44.24% | 46.99% | -0.45% | -0.74% |
| P/E | 38.6x | 40.8x | 36.1x | 25.4x | -14.8x | 20.8x | 18.8x | 17.9x |
| PBR | 6.13x | 5.64x | 5.48x | 3.93x | 2.57x | 3.72x | 3.4x | 3.1x |
| PEG | - | -7.25x | 1.8x | 1.9x | 0x | -0x | 1.8x | 3.57x |
| Capitalization / Revenue | 8.45x | 6.69x | 6.43x | 4.89x | 2.41x | 3.84x | 3.7x | 3.55x |
| EV / Revenue | 8.38x | 7.49x | 7.14x | 5.46x | 3x | 4.42x | 4.25x | 4.05x |
| EV / EBITDA | 24.6x | 25.6x | 22.3x | 16.5x | 10.7x | 13.7x | 13x | 12.3x |
| EV / EBIT | 30.2x | 32.5x | 27.7x | 19x | 10.3x | 16x | 15.1x | 14.3x |
| EV / FCF | 57.1x | 72.6x | 55.2x | 29.1x | 16.5x | 22.1x | 23.6x | 22.3x |
| FCF Yield | 1.75% | 1.38% | 1.81% | 3.44% | 6.05% | 4.52% | 4.23% | 4.48% |
| Dividend per Share 2 | 2.22 | 2.36 | 2.64 | 2.92 | 2.92 | 2.998 | 3.183 | 3.412 |
| Rate of return | 1.2% | 1.28% | 1.34% | 1.86% | 3.68% | 2.38% | 2.52% | 2.7% |
| EPS 2 | 4.8 | 4.53 | 5.45 | 6.17 | -5.35 | 6.076 | 6.702 | 7.038 |
| Distribution rate | 46.3% | 52.1% | 48.4% | 47.3% | -54.6% | 49.3% | 47.5% | 48.5% |
| Net sales 1 | 10,562 | 13,310 | 14,800 | 15,558 | 15,797 | 15,757 | 16,316 | 17,015 |
| EBITDA 1 | 3,596 | 3,900 | 4,750 | 5,151 | 4,438 | 5,084 | 5,323 | 5,597 |
| EBIT 1 | 2,927 | 3,069 | 3,812 | 4,468 | 4,620 | 4,367 | 4,590 | 4,824 |
| Net income 1 | 2,255 | 2,194 | 2,642 | 3,002 | -2,579 | 2,822 | 3,149 | 3,348 |
| Net Debt 1 | -778.6 | 10,679 | 10,526 | 8,981 | 9,383 | 9,232 | 8,919 | 8,403 |
| Reference price 2 | 185.38 | 184.61 | 196.96 | 157.01 | 79.38 | 126.20 | 126.20 | 126.20 |
| Nbr of stocks (in thousands) | 481,706 | 482,372 | 483,253 | 484,212 | 478,912 | 478,912 | - | - |
| Announcement Date | 16/8/22 | 14/8/23 | 12/8/24 | 18/8/25 | 17/8/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.85x | 4.44x | 13.75x | 2.37% | 60.66B | |
| 33.76x | 12.26x | 24.76x | 0.58% | 1,060B | |
| 28.75x | 6.35x | 18.21x | 2.07% | 623B | |
| 34.38x | 7.99x | 16.52x | 2.56% | 480B | |
| 103.88x | 5.82x | 24.82x | 2.39% | 352B | |
| 19.43x | 4.75x | 11.8x | 2.78% | 345B | |
| 20.28x | 5.28x | 13.08x | 3.01% | 274B | |
| 20.79x | 4.27x | 12.2x | 2.08% | 249B | |
| 26.09x | 6.8x | 12.11x | 2.44% | 223B | |
| -44.42x | 6.54x | 25.48x | 2.24% | 182B | |
| Average | 26.38x | 6.45x | 17.27x | 2.25% | 384.87B | |
| Weighted average by Cap. | 32.01x | 7.78x | 19.00x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CSL Stock
- Valuation CSL Limited
Select your edition
All financial news and data tailored to specific country editions
